Morgan Stanley analysts support the financial institution's positive coverage of Ambu, which was initiated with the recommendation "overweight" and a DKK 350 (USD 56.4) price target.
The team of analysts from Morgan Stanley note that Ambu is stealing away a large share of growth opportunities from its competitors with 12 new product launches coming up in the next 18 months, according to media Bloomberg News.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.